Third Rock Ventures GP V, LP bought $6.2M of Septerna (SEPN)
Executed Feb 20 2025, disclosed Feb 24 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Feb 24 2025), the stock returned +2.2% (delay-adjusted); from the execution session (Feb 20 2025), +12.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Third Rock Ventures GP V, LP (10% owner) filed 2 Form 4 reports as a reporting entity in the past 24 months (2 purchases, 0 sales), most often in Septerna, Inc. (SEPN). Across 2 priced purchase filings, the average 21-session return was +7.2% from execution and +6.7% from disclosure (delay-adjusted; derived). The largest single filing was $6.2M of SEPN (1,040,342 sh across 2 lots, as filed), executed Feb 20 2025.
Healthcare · Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule produc…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→18,861 sh × $6.00
Exec Feb 24 2025
Filed Feb 26 2025 · 5:30 PM ET